Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats

Table 1 Pathological observation of liver condition

Group	n	Liver condition					U
		0	I	II	III	IV
Model	13	0	0	0	4	9
High-dose	12	0	5	3	2	2	3.26a
Medium-dose	14	0	6	4	3	1	4.17b
Low-dose	13	0	3	2	6	2	2.96a

U represents the RIDIT value of the two groups, P < 0.05 indicates U > 1.96, P < 0.01 indicates U > 2.58.

^aP < 0.05,

^bP < 0.01 vs model group.

Table 2 Serum level of ALT, ALB, GLB, TG and liver HYP (mean ± SD)

Group	n	ALT (IU/L)	ALB (g/L)	GLB (g/L)	TG (mmol/L)	Liver HYP (μg/mg protein)
Control	15	67.58 ± 11.21	41.12 ± 2.54	21.48 ± 3.24	0.39 ± 0.08	9.80 ± 1.07
Model	13	412 ± 94.50	28.49 ± 4.93	35.62 ± 3.28	0.95 ± 0.16	27.54 ± 4.32
High-dose	12	173.09 ± 24.62bc	35.73 ± 2.73a	25.59 ± 3.61a	0.61 ± 0.10b	12.83 ± 2.54ad
Medium-dose	14	113.76 ± 14.91ad	37.51 ± 3.17a	24.82 ± 2.73a	0.51 ± 0.06a	16.20 ± 3.12bd
Low-dose	13	152.86 ± 19.19bc	34.31 ± 4.52b	27.51 ± 2.41b	0.58 ± 0.07b	14.38 ± 2.18bd

ALT: Alanine aminotransferase; ALB: Albumin; GLB: Globulin; TG: Triglyeride; HYP: Hydroxyproline.

^aP < 0.05,

^bP < 0.01 vs control group;

^cP < 0.05,

^dP < 0.01 vs model group.